How to Launch Telemedicine Platform in China: 2026 Guide for Foreign Companies
China’s telemedicine market is projected to reach CNY 95 billion by 2026, yet foreign companies face a regulatory framework that requires 3 mandatory government approvals (Internet Hospital License, Medical Institution Practice License, and ICP License), strict data localization under the Personal Information Protection Law (PIPL), and a foreign investment structure that limits equity to a maximum of 50% in value-added telemedicine services under the 2025 Foreign Investment Negative List (外商投资负面清单, wàishāng tóuzī fùmiàn qīngdān). This guide provides a step-by-step pathway through licensing, partnership structures, and compliance requirements for foreign companies targeting China’s digital health market in 2026.
China’s Telemedicine Regulatory Landscape in 2026
Foreign companies entering China’s telemedicine space must navigate three primary regulators: the National Health Commission (NHC), which governs medical practice and internet hospital licensing; the Cyberspace Administration of China (CAC), which enforces data security and cross-border data transfer rules; and the Ministry of Industry and Information Technology (MIIT), which oversees telecommunications and ICP licensing. Each regulator imposes layered requirements that create a cumulative compliance burden.
By early 2025, China had over 2,400 registered internet hospitals (互联网医院, hùliánwǎng yīyuàn), up from roughly 1,600 in 2022. However, fewer than 5% of these are operated by foreign-invested entities, according to NHC data. The 2025 update to the Foreign Investment Negative List maintained the restriction that value-added telemedicine services — including remote diagnosis, treatment, and electronic prescription — fall under “restricted foreign investment” categories, requiring a Chinese controlling partner when operating directly with patients.
Three core regulations define the 2026 operating environment for foreign-backed telemedicine platforms: the Internet Diagnosis and Treatment Management Measures (2018), the Internet Hospital Management Measures (2018), and the Data Security Law (2021) along with its sectoral implementation rules for healthcare. Additionally, the NHC’s 2024 Guidelines on Digital Health Data Governance introduced specific rules for AI-assisted diagnosis and remote monitoring data, which directly impact foreign platform operators using algorithmic triage or decision-support tools.
The Three Approved Market Entry Models for Foreign Companies
Foreign companies cannot simply register a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) and launch a telemedicine platform. China’s regulations restrict direct foreign ownership of internet hospitals to no more than 50% equity when the platform provides direct patient consultation, electronic prescriptions, or diagnosis. Foreign companies have three viable entry models, each with distinct timelines, costs, and control profiles.
| Model | Description | Regulatory Approval | Timeline | Foreign Equity | Est. Cost (CNY) | Data Control |
|---|---|---|---|---|---|---|
| 1. WFOE + Hospital JV | WFOE forms a joint venture with a licensed Grade 2+ Chinese hospital to operate an internet hospital | Internet Hospital License, Medical Institution Practice License, ICP, PIPL certification | 12–18 months | ≤ 50% | 8–15 million | JV controls data; foreign partner has limited access |
| 2. Joint Venture with Healthcare Provider | Foreign company invests in a Chinese healthcare group that already holds an internet hospital license | Shareholders’ agreement, anti-monopoly review, ICP (if new services added) | 6–12 months | ≤ 49% | 5–12 million | Data governed by JV governance agreement |
| 3. B2B Technology Provider | WFOE supplies SaaS, PaaS, or AI tools to licensed Chinese hospitals without providing direct patient services | ICP License (if data processing), PIPL compliance, Class I/II medical device registration (if applicable) | 4–8 months | 100% WFOE | 2–6 million | WFOE retains control of aggregated non-health data |
Model 3 (B2B Technology Provider) is the most common entry path for foreign companies in 2025–2026, because it avoids the equity cap entirely. Under this model, the foreign WFOE provides telemedicine platform infrastructure, including video consultation software, AI triage algorithms, and electronic health record (EHR) integration modules, to licensed Chinese hospitals. The hospital retains all patient-facing responsibilities and clinical liability. The WFOE does not need an Internet Hospital License because it is not providing 互联网诊疗 (hùliánwǎng zhěnliáo, internet diagnosis and treatment) directly to patients.
In contrast, Model 1 requires the Internet Hospital License (互联网医院牌照, hùliánwǎng yīyuàn páizhào), which can only be held by a Chinese entity — typically a public hospital or a Chinese-controlled JV. The foreign partner’s role is limited to technology, capital, and operational support, and all clinical data must be processed through servers in mainland China under the hospital’s management.
Data Compliance: PIPL, DSL, and Healthcare Data Sovereignty
Data compliance is the single most underestimated barrier for foreign telemedicine platforms in China. Under the Personal Information Protection Law (PIPL) and the Data Security Law (DSL), all healthcare data — including patient records, diagnostic images, prescription data, and biometric information — is classified as “important data” (重要数据, zhòngyào shùjù) by sectoral regulations. This classification triggers three critical obligations for foreign-backed entities.
First, data localization requires that all healthcare data collected within China be stored and processed on servers physically located in mainland China. The 2024 Health Data Security Management Measures further mandate that internet hospitals maintain separate data lakes for clinical records, with access logging and audit trails that must be retained for a minimum of 5 years. Foreign companies that attempt to mirror data to offshore servers for AI training risk penalties of up to CNY 50 million or 5% of annual revenue under PIPL.
Second, cross-border data transfer for healthcare data is effectively prohibited except under very narrow exceptions, such as patients explicitly consenting to transfer for international second-opinion consultation. Even then, the CAC requires a security assessment (安全评估, ānquán pínggū) for any transfer of important data abroad. As of early 2026, the CAC has approved fewer than 15 healthcare-related cross-border data transfer applications, all for multinational pharmaceutical companies conducting clinical trials — none for telemedicine platforms.
Third, AI governance regulations introduced by the NHC in 2024 require that any telemedicine platform using AI-assisted diagnosis or triage must register the algorithm under the Measures for the Management of Deep Synthesis and obtain a Medical Device Registration Certificate (医疗器械注册证, yīliáo qìxiè zhùcè zhèng) if the algorithm is classified as a Class II or Class III medical device. Foreign AI models that have been trained on non-Chinese patient populations must undergo additional clinical validation using Chinese patient data — a process that typically takes 6–12 months and costs CNY 1–3 million.
Decision Framework: Choosing Your Market Entry Model
If you own proprietary clinical AI algorithms and need to operate the patient-facing platform to validate your technology, choose Model 1 (WFOE + Hospital JV). This model gives you direct operational control over the telemedicine workflow, user experience, and data collection design — provided you partner with a Grade 3 hospital that already holds an internet hospital license or is willing to apply for one. Expect a 14–18 month timeline and legal costs of CNY 8–15 million for the JV structure, licensing, and compliance setup.
If you offer a mature SaaS or PaaS platform and want to serve multiple Chinese hospitals without taking clinical liability, choose Model 3 (B2B Technology Provider). This is the fastest path to revenue: you keep 100% equity in your WFOE, avoid the Internet Hospital License application entirely, and can sign your first hospital contract within 4–6 months. The trade-off is that you do not own the patient relationship or the clinical dataset — the hospital retains those assets.
If you already have a Chinese joint venture partner and want a balanced control structure with shared risk, choose Model 2 (JV with Healthcare Provider). This works well when your partner is a private healthcare group with multiple hospitals and an existing internet hospital license. You avoid the 12-month internet hospital application cycle, but you must carefully negotiate data governance rights in the JV agreement — a common point of friction that can delay deals by 2–4 months.
2026 Licensing Pathway: 7 Steps from WFOE to Operation
The licensing pathway for a foreign telemedicine platform under Model 1 requires the following sequential steps. Under Model 3 (B2B), steps 3 and 6 are replaced by a simpler technology service agreement review.
- Establish a WFOE with a registered business scope that includes “technical development for medical information systems” and “sale of computer software.” Do not include “internet medical services” in the business scope unless you already have a hospital JV partner. (Timeline: 4–6 weeks.)
- Obtain the ICP License (增值电信业务经营许可证, zēngzhí diànxìn yèwù jīngyīng xǔkězhèng) for online data processing and transaction processing services. The WFOE must have been operating for at least 3 months and have a registered capital of at least CNY 1 million. (Timeline: 8–12 weeks.)
- Secure a hospital JV partner that holds or is willing to apply for an Internet Hospital License. The Chinese partner must own at least 50.01% of the JV entity. Draft a JV agreement that clearly defines data ownership, IP rights, profit sharing, and clinical liability. (Timeline: 8–16 weeks.)
- Apply for the Internet Hospital License through the NHC provincial office where the JV entity is registered. Required documents include the JV agreement, hospital practice license, technology platform description, data security plan, and a list of at least 10 licensed physicians who will provide remote consultations. (Timeline: 12–24 weeks.)
- Complete PIPL compliance certification through a CAC-approved certification body. This includes a data protection impact assessment (DPIA), appointment of a data protection officer (DPO) in China, and implementation of data encryption and access controls. (Timeline: 8–12 weeks, can run in parallel with steps 3 and 4.)
- Register the telemedicine platform with the provincial NHC and obtain the Medical Institution Practice License extension for the internet hospital. This step also requires a technical review of the platform’s video consultation system, EHR integration, and prescription management module. (Timeline: 4–8 weeks.)
- Complete a 3-month pilot operation under NHC supervision before full commercial launch. During this period, the platform must operate with a restricted patient volume and submit monthly compliance reports. (Timeline: 12 weeks.)
Total estimated timeline under Model 1: 12–18 months from WFOE establishment to full commercial operation. Many foreign companies report that the hospital JV negotiation (step 3) is the most unpredictable phase, often taking 3–6 months longer than anticipated.
Three Critical Pitfalls for Foreign Telemedicine Platforms
NEXT STEPS
- Read our Digital Health Regulatory Overview for 2026 — a detailed breakdown of NHC, CAC, and MIIT requirements for foreign-backed telemedicine platforms. View the Digital Health Regulatory Guide →
- Explore our guide on Structuring a Hospital Joint Venture in China — covers equity splits, IP ownership, data governance clauses, and exit strategies for foreign companies partnering with Chinese hospitals. Read the JV Structuring Guide →
- Download the China Telemedicine Compliance Checklist — a 45-item checklist covering licensing, data localization, AI registration, and cross-border transfer requirements, updated for 2026 regulations. Get the Compliance Checklist →
— China Gateway 360 —
Remote China market entry support, built around execution.
